MX388408B - Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv - Google Patents

Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv

Info

Publication number
MX388408B
MX388408B MX2019002678A MX2019002678A MX388408B MX 388408 B MX388408 B MX 388408B MX 2019002678 A MX2019002678 A MX 2019002678A MX 2019002678 A MX2019002678 A MX 2019002678A MX 388408 B MX388408 B MX 388408B
Authority
MX
Mexico
Prior art keywords
tlr7 agonist
capsid assembly
hbv capsid
combined treatment
assembly inhibitor
Prior art date
Application number
MX2019002678A
Other languages
English (en)
Other versions
MX2019002678A (es
Inventor
Lu Gao
Lue Dai
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019002678A publication Critical patent/MX2019002678A/es
Publication of MX388408B publication Critical patent/MX388408B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se dirige a composiciones y métodos para tratar infección de virus de hepatitis B virus. En particular, la presente invención se dirige a una terapia de combinación que comprende administración de un agonista de TLR7 y un inhibidor de montaje de cápsida de HBV para el uso en el tratamiento de paciente con hepatitis B crónica.
MX2019002678A 2016-09-13 2017-09-11 Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv MX388408B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016098892 2016-09-13
PCT/EP2017/072671 WO2018050571A1 (en) 2016-09-13 2017-09-11 Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Publications (2)

Publication Number Publication Date
MX2019002678A MX2019002678A (es) 2019-05-20
MX388408B true MX388408B (es) 2025-03-19

Family

ID=59859071

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002678A MX388408B (es) 2016-09-13 2017-09-11 Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
MX2021014771A MX2021014771A (es) 2016-09-13 2019-03-07 Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014771A MX2021014771A (es) 2016-09-13 2019-03-07 Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.

Country Status (14)

Country Link
US (1) US11337982B2 (es)
EP (2) EP3512556B1 (es)
JP (2) JP7101663B2 (es)
KR (1) KR102497701B1 (es)
CN (1) CN109715214B (es)
AU (1) AU2017326400B2 (es)
BR (1) BR112019004560A2 (es)
CA (1) CA3034185A1 (es)
ES (1) ES2894605T3 (es)
IL (2) IL264926B (es)
MX (2) MX388408B (es)
PL (1) PL3512556T3 (es)
TW (1) TWI720250B (es)
WO (1) WO2018050571A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3114128T3 (pl) * 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
CN107427514B (zh) 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
PE20211456A1 (es) * 2018-02-28 2021-08-05 Hoffmann La Roche Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CA3124317A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
AU2020249331B2 (en) 2019-03-25 2026-02-05 F. Hoffmann-La Roche Ag Solid forms of a compound of HBV core protein allosteric modifier
TW202122392A (zh) * 2019-07-31 2021-06-16 愛爾蘭商健生科學愛爾蘭無限公司 二氫嘧啶衍生物及其於治療hbv感染或hbv誘發的疾病之用途
EP4031140A1 (en) * 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Method of treating hbv infection using a core protein allosteric modulator
CN119679953A (zh) * 2023-09-22 2025-03-25 苏州申拓医药科技有限公司 含tlr7/8选择性激动剂和hbv衣壳装配抑制剂的药物组合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
DE10012824A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
WO2005085462A1 (en) 2004-02-27 2005-09-15 Dsm Ip Assets B.V. Enzymatic preparation of an enantiomerically enriched beta-2-amino acids
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CA2621809A1 (en) 2005-09-22 2007-04-05 The Scripps Research Institute Alkoxy indolinone based protein kinase inhibitors
JP2009542645A (ja) * 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
EP2098526B1 (en) 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
JP5816087B2 (ja) 2008-08-29 2015-11-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Smoアンタゴニストとしての飽和二環式複素環誘導体
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
WO2010069147A1 (zh) 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
MX2014011749A (es) 2012-03-31 2015-01-22 Hoffmann La Roche 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b.
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US8993771B2 (en) * 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CN104650069B (zh) 2013-11-19 2019-04-19 广东东阳光药业有限公司 4-甲基二氢嘧啶类化合物及其在药物中的应用
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
CN112898308B (zh) 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EP3204392A1 (en) 2014-10-11 2017-08-16 F. Hoffmann-La Roche AG Compounds for use in the treatment of infectious diseases
CN107427514B (zh) * 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
RU2751349C2 (ru) 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
CA3034185A1 (en) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Also Published As

Publication number Publication date
TW201811371A (zh) 2018-04-01
EP3512556B1 (en) 2021-08-18
KR102497701B1 (ko) 2023-02-09
JP7101663B2 (ja) 2022-07-15
ES2894605T3 (es) 2022-02-15
PL3512556T3 (pl) 2021-12-27
JP2022130672A (ja) 2022-09-06
US20190298726A1 (en) 2019-10-03
CN109715214A (zh) 2019-05-03
IL287545B2 (en) 2023-02-01
CN109715214B (zh) 2022-03-04
WO2018050571A1 (en) 2018-03-22
CA3034185A1 (en) 2018-03-22
EP3512556A1 (en) 2019-07-24
IL287545B (en) 2022-10-01
JP2019526610A (ja) 2019-09-19
AU2017326400B2 (en) 2023-03-30
AU2017326400A1 (en) 2019-02-21
MX2019002678A (es) 2019-05-20
KR20190053219A (ko) 2019-05-17
US11337982B2 (en) 2022-05-24
MX2021014771A (es) 2022-01-18
IL264926B (en) 2021-12-01
EP3970750A1 (en) 2022-03-23
TWI720250B (zh) 2021-03-01
IL287545A (en) 2021-12-01
BR112019004560A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
MX2019002678A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
MX2018014573A (es) Vacuna contra el virus del zika.
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CR20160520A (es) Oligómeros y conjugados de oligómeros
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
AR111908A1 (es) Composiciones terapéuticas y métodos de tratamiento de hepatitis b
MX373231B (es) Agente anticancerigeno.
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX381896B (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.